Jeff Jerman
YOU?
Author Swipe
View article: Identification of a novel specific small-molecule melanocortin-2-receptor antagonist
Identification of a novel specific small-molecule melanocortin-2-receptor antagonist Open
The overproduction of adrenocorticotropic hormone (ACTH), in conditions such as Cushing’s disease and congenital adrenal hyperplasia (CAH), leads to significant morbidity. Current treatment with glucocorticoids does not adequately suppress…
View article: Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2
Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2 Open
TREK2 (KCNK10, K2P10.1) is a two-pore domain potassium (K2P) channel and a potential target for the treatment of pain. Like the majority of the K2P superfamily, there is currently a lack of useful pharmacological tools to study TREK2. Here…
View article: ACTH Antagonists
ACTH Antagonists Open
Adrenocorticotropin (ACTH) acts via a highly selective receptor that is a member of the melanocortin receptor subfamily of type 1 G protein-coupled receptors. The ACTH receptor, also known as the melanocortin 2 receptor (MC2R), is unusual …